Press Releases

Date Title
Toggle Summary vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session Subgroup Data Discussing the Effect of Azeliragon in Patients with Dementia and Diabetes to be Presented during Poster Session HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 16, 2018-- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 30, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced it will be featured as a presenting
View HTML
Toggle Summary vTv Therapeutics Announces Second Quarter 2018 Results and Update
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 3, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2018 , and provided an update on recent achievements and upcoming events. “Since our announcement regarding the topline results from
View HTML
Toggle Summary vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that
View HTML
Toggle Summary vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that
View HTML
Toggle Summary vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 12, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints.
View HTML
Toggle Summary vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 12, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints.
View HTML
Toggle Summary vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTv’s PDE4 Inhibitor in China and Other Pacific Rim Territories
HIGH POINT, N.C. --(BUSINESS WIRE)--May 31, 2018-- vTv Therapeutics Inc.  (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program
View HTML
Toggle Summary vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTv’s PDE4 Inhibitor in China and Other Pacific Rim Territories
HIGH POINT, N.C. --(BUSINESS WIRE)--May 31, 2018-- vTv Therapeutics Inc.  (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with  Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program
View HTML
Toggle Summary vTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights
HIGH POINT, N.C. --(BUSINESS WIRE)--May 15, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial and operational results for the first quarter that ended March 31, 2018 . “We continue to make progress on all of our major programs,” said Steve Holcombe , chief executive officer, vTv
View HTML